Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea’s (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights

While Eylea holds the second-place position, newcomer Vabysmo (Genentech) has already captured a small piece of the market and is the anticipated first switch for many current Eylea patients EXTON, Pa., Nov. 3, 2022 /PRNewswire/ -- Despite the availability of on-label products to treat...

Click to view original post